Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Yeon Hee Park
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06616987CT.gov Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT04762901CT.gov LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | — | Withdrawn | — | — | — |
NCT03252431CT.gov Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | — | Completed | — | — | — |
NCT02768714CT.gov Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy | — | Withdrawn | — | — | — |
NCT02953340CT.gov SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide | — | Completed | — | — | — |
NCT03381417CT.gov Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients. | — | Completed | — | — | — |
NCT02790580CT.gov Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients | — | Unknown | — | — | — |
NCT02643420CT.gov SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) | — | Completed | — | — | — |
NCT01712009CT.gov NOLAN: Naproxen or Loratadine and Neulasta | — | Completed | — | — | — |
NCT01648322CT.gov Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy | — | Completed | — | — | — |
Show 19 more trialsShow fewer
NCT01516736CT.gov Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim | — | Completed | — | — | — |
NCT01498588CT.gov Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT01416389CT.gov A Study of LY2523355 in Participants With Breast Cancer | — | Completed | — | — | — |
NCT00856492CT.gov S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT01057069CT.gov Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT00777673CT.gov Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | — | Unknown | — | — | — |
NCT00645333CT.gov Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00615901CT.gov Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00404066CT.gov Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | — | Completed | — | — | — |
NCT00394251CT.gov Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | — | Completed | — | — | — |
NCT00436709CT.gov Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer | — | Unknown | — | — | — |
NCT00346229CT.gov Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer | — | Terminated | — | — | — |
NCT00310089CT.gov AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00261313CT.gov ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer | — | Completed | — | — | — |
NCT00256360CT.gov Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer | — | Completed | — | — | — |
NCT00232479CT.gov Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer | — | Completed | — | — | — |
NCT00286819CT.gov Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer | — | Completed | — | — | — |
NCT00146562CT.gov Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | — | Completed | — | — | — |
NCT00063934CT.gov Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegfilgrastim (this asset) | Yeon Hee Park | Approved | BB · 67 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Pegfilgrastim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neutropenia | — | P4 | BBB · 76 |
| Primary Peritoneal Carcinoma | — | P2/3 | BBB · 73 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegfilgrastim in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegfilgrastim-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →